A new study in Clinical Epidemiology and Global Health features the Glivec®Patient Assistance Program (GIPAP) and reveals that “chronic myelocytic leukemia (CML) is diagnosed at an earlier age in poorer populations than in more affluent populations.” The study focused on India’s CML population to investigate other possible contributors to early age at onset. The team of authors include our very own South Asia Region Head Viji Venkatesh, and Max CEO Pat Garcia-Gonzalez, as well as Paul H. Levine, Kunal Ajmera, Brenna O’Neill, Heather J. Hoffman.
The study is only available to the public for a limited time so if you know a physician or researcher that would benefit from this study, share it today!
The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.
Having a baby is a major decision, especially for Thao from Vietnam, a cancer patient who had to pause her treatment in order to have a safe pregnancy. Thao shares how she found support through her patient group, her family, and The Max Foundation.
How we continue providing emotional support for people facing cancer throughout COVID-19
I found myself reflecting about vulnerability. In a way, vulnerability is an impact. After hours of phone calls throughout the year, families have opened themselves up to me. The vulnerability is not just a spur of the moment but hopefully built on mutual trust and respect. I gain a new perspective about vulnerability – it draws out your strength when you respond to it with care.
